| Literature DB >> 17496998 |
Abstract
The organosilicon derivatives ofEntities:
Year: 2006 PMID: 17496998 PMCID: PMC1686292 DOI: 10.1155/BCA/2006/13743
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Scheme 1Analysis and physical properties of the ligand and its silicon complexes.
| Compound | Elemental analysis (%) | ||||||||||||
|
| |||||||||||||
| Reactant (g) | Colour | Yield | MP |
|
|
|
|
|
| Mol Wt | |||
| M | LH | Na | and state | (%) | (°C) | Found | Found | Found | Found | Found | Found | Found | |
| (Calcd) | (Calcd) | (Calcd) | (Calcd) | (Calcd) | (Calcd) | (Calcd) | |||||||
|
| |||||||||||||
| (2-Ac-F-StH) | — | — | — | Light yellow | 73 | 124–130 | 51.62 | 3.51 | 11.84 | 18.19 | — | — | 325 |
| (51.86) | (3.77) | (12.09) | (18.45) | (347.39) | |||||||||
|
| 0.38 | 1.02 | 0.07 | Dark brown | 74 | 71–73 | 46.18 | 3.88 | 9.26 | 14.19 | 6.07 | 8.00 | 412 |
| solid | (46.40) | (4.12) | (9.55) | (14.57) | (6.38) | (8.05) | (439.99) | ||||||
|
| 0.11 | 0.61 | 0.04 | Light brown | 76 | 109–111 | 50.99 | 3.67 | 10.77 | 16.70 | 3.48 | — | 738 |
| solid | (51.18) | (4.02) | (11.19) | (17.07) | (3.74) | (750.92) | |||||||
|
| 0.48 | 0.66 | 0.04 | Dark brown | 74 | 149–151 | 57.15 | 3.58 | 7.09 | 11.00 | 4.71 | 5.92 | 542 |
| solid | (57.48) | (3.93) | (7.44) | (11.36) | (4.97) | (6.28) | (564.13) | ||||||
|
| 0.29 | 0.81 | 0.05 | Dark brown | 77 | 155–157 | 57.31 | 3.74 | 9.42 | 14.19 | 3.00 | — | 858 |
| solid | (57.64) | (3.91) | (9.60) | (14.65) | (3.20) | (875.05) | |||||||
|
| 0.51 | 0.60 | 0.04 | Brown solid | 81 | 90–92 | 65.02 | 4.12 | 6.68 | 10.19 | 4.22 | — | 588 |
| (65.42) | (4.49) | (6.93) | (10.58) | (4.63) | (605.78) | ||||||||
*M = silicon compound, LH = ligand, and Na = sodium metal.
Scheme 2General equations showing the formations of the sodium salt and the complexes (R = Me and Ph).
UV spectral data of the ligand and its silicon complexes.
| Ligand/complex |
|
|
|
| >C=N |
| >C=N | |
|
| |||
| (2-Ac-F-StH) | 370 | 255 | 285 |
|
| 359 | 273 | 281 |
|
| 362 | 276 | 278 |
|
| 351 | 280 | 275 |
|
| 355 | 285 | 271 |
|
| 353 | 290 | 268 |
IR spectral data (cm−1) of the ligand and its silicon complexes.
| Compound/ligand |
|
|
|
|
|
| ||||
|
| 3400-3150 (m) | 1628 (vs) | — | — |
|
| — | 1622 | 577 w | 423 m |
|
| — | 1625 | 582 w | — |
|
| — | 1619 | 574 w | 439 m |
|
| — | 1613 | 576 w | — |
|
| — | 1616 | 570 w | — |
*m = medium, vs = very strong, and w = weak.
NMR spectral data (δ, ppm) of the ligand and its silicon complexes.
| Ligand/complex |
|
|
| Aromatic proton |
|
|
| |||||
|
| — | 2.10 (3H, s | 10.54 (br | 8.10-6.92 (m) | — |
|
| 1.01 (1s, 6H) | 2.25 (3H, s) | — | 8.36-7.20 (m) | −98 (ppm) |
|
| 1.13 (s, 6H) | 2.17 (6H, s) | — | 8.784-7.00 (m) | −128 (ppm) |
|
| — | 2.22 (3H, s) | — | 8.48-6.95 (m) | −94 (ppm) |
|
| — | 2.15 (6H, s) | — | 8.56-7.30 (m) | −110 (ppm) |
|
| — | 2.19 (3H, s) | — | 8.51-7.14 (m) | −91 (ppm) |
*m = multiplet, br = broad, and s = singlet.
NMR spectral data (δ, ppm) of the ligand and its silicon complexes.
| Ligand/complex | Azomethine C-atom |
|
|
|
|
|
| C11 |
|
|
|
|
|
| ||||
|
| ||||||||
|
| 155.91 | — | 146.02 | 138.99 | 120.98 | 143.94 | 152.60 | 151.80 |
| 128.01 | 122.46 | 124.01 | 125.98 | 150.00 | ||||
|
| 144.76 | 13.98 | 148.91 | 139.21 | 121.12 | 142.92 | 149.20 | 150.70 |
| 125.96 | 120.24 | 123.67 | 119.76 | 150.95 | ||||
|
| 148.51 | 15.01 | 147.69 | 140.96 | 121.32 | 143.01 | 149.45 | 149.85 |
| 124.21 | 120.96 | 122.21 | 119.10 | 151.00 | ||||
|
| 153.46 | — | 146.36 | 137.01 | 120.76 | 142.10 | 151.20 | 149.70 |
| 126.01 | 121.78 | 119.98 | 122.46 | 150.15 | ||||
|
| 146.76 | — | 145.16 | 138.06 | 127.92 | 143.21 | 147.20 | 150.12 |
| 128.96 | 121.02 | 120.21 | 123.74 | 149.80 | ||||
|
| 154.90 | — | 144.05 | 133.42 | 120.81 | 143.40 | 148.78 | 149.40 |
| 127.01 | 121.98 | 123.32 | 124.86 | 150.55 | ||||
Figure 1(a) The penta-coordinated trigonal bipyramidal and (b) hexa-coordinated octahedral geometries R = Me/Ph and X = Ph/Cl.
Fungicidal screening data of the ligand and its silicon complexes inhibition percentage after 96 hours and SD values (25, 50, and 100 are concentrations in ppm).
| Ligand/complex |
|
|
|
| ||||||||
|
| ||||||||||||
| 25 | 50 | 100 | 25 | 50 | 100 | 25 | 50 | 100 | 25 | 50 | 100 | |
|
| ||||||||||||
|
| 34 | 53 | 61 | 35 | 50 | 68 | 39 | 56 | 65 | 43 | 60 | 66 |
| (50.72) | (38.37) | (37.75) | (51.38) | (39.02) | (29.16) | (44.28) | (38.46) | (35.00) | (39.44) | (30.23) | (34.00) | |
|
| ||||||||||||
|
| 37 | 56 | 72 | 38 | 52 | 71 | 42 | 59 | 71 | 45 | 62 | 68 |
| (46.37) | (34.88) | (36.11) | (47.22) | (36.58) | (26.04) | (40.00) | (35.16) | (29.00) | (36.62) | (27.91) | (32) | |
|
| ||||||||||||
|
| 42 | 63 | 78 | 41 | 57 | 74 | 46 | 65 | 74 | 47 | 65 | 72 |
| (39.13) | (26.74) | (20.40) | (43.05) | (30.48) | (22.44) | (35.28) | (28.57) | (26.00) | (33.80) | (24.42) | (28.00) | |
|
| ||||||||||||
|
| 38 | 57 | 76 | 40 | 53 | 72 | 43 | 61 | 73 | 46 | 63 | 70 |
| (44.92) | (33.72) | (22.44) | (44.44) | (35.36) | (26.53) | (38.57) | (32.96) | (27.00) | (35.21) | (26.74) | (30.00) | |
|
| ||||||||||||
|
| 44 | 66 | 82 | 47 | 61 | 80 | 48 | 67 | 78 | 49 | 66 | 76 |
| (36.23) | (23.25) | (16.32) | (34.72) | (25.60) | (18.36) | (31.42) | (26.37) | (22.00) | (30.99) | (23.26) | (24.00) | |
|
| ||||||||||||
|
| 40 | 60 | 80 | 42 | 54 | 73 | 45 | 63 | 75 | 47 | 64 | 71 |
| (42.02) | (30.23) | (18.36) | (41.66) | (34.14) | (25.51) | (35.71) | (30.76) | (25.00) | (33.80) | (25.58) | (29.00) | |
|
| ||||||||||||
| Bavistin | 69 | 86 | 98 | 72 | 82 | 96 | 70 | 91 | 100 | 71 | 86 | 100 |
Adulticidal screening data of the ligand and its silicon complexes (100 and 200 are concentrations in ppm).
| Ligand/complex | Dose level | Average no. of | Average mortality | % adult | % corrected | |
| adults in each vial | after 48 hours | mortality | mortality | |||
|
| ||||||
|
| 100 | 20 | 4 | 20 | 15.78 | |
| 200 | 20 | 6 | 30 | 26.31 | ||
|
| 100 | 20 | 7 | 35 | 31.57 | |
| 200 | 20 | 11 | 55 | 52.63 | ||
|
| 100 | 20 | 11 | 55 | 52.63 | |
| 200 | 20 | 14 | 70 | 68.42 | ||
|
| 100 | 20 | 9 | 45 | 42.10 | |
| 200 | 20 | 12 | 60 | 57.10 | ||
|
| 100 | 20 | 12 | 60 | 57.89 | |
| 200 | 20 | 15 | 75 | 57.89 | ||
|
| 100 | 20 | 10 | 50 | 73.68 | |
| 200 | 20 | 4 | 70 | 47.36 | ||
| Control | — | 20 | 1 | 5 | 68.42 | |
Ovicidal screening data of the ligand and its silicon complexes (100 and 200 are concentrations in ppm).
| Ligand/complex | Dose level | Average no. of | Average no. of | % eggs | % eggs | % corrected |
| eggs hatched | eggs unhatched | hatching | unhatched | mortality | ||
|
| ||||||
|
| 100 | 15 | 5 | 75 | 25 | 21.05 |
| 200 | 11 | 9 | 55 | 45 | 42.10 | |
|
| 100 | 13 | 7 | 65 | 35 | 31.57 |
| 200 | 9 | 11 | 45 | 55 | 52.63 | |
|
| 100 | 9 | 11 | 45 | 55 | 52.63 |
| 200 | 7 | 13 | 35 | 65 | 63.15 | |
|
| 100 | 11 | 9 | 55 | 45 | 42.10 |
| 200 | 7 | 13 | 35 | 65 | 63.15 | |
|
| 100 | 8 | 12 | 40 | 60 | 57.89 |
| 200 | 5 | 15 | 25 | 75 | 73.68 | |
|
| 100 | 10 | 10 | 50 | 50 | 47.36 |
| 200 | 7 | 13 | 35 | 65 | 63.15 | |
| Control | — | 19 | 1 | 95 | 5 | — |
Larvicidal screening data of the ligand and its silicon complexes (100 and 200 are concentrations in ppm).
| Ligand/complex | Dose level | Average no. of | Average no. of | % pupal | % larval | % corrected |
| pupal formed | dead larvae | formation | mortality | mortality | ||
|
| ||||||
|
| 100 | 16 | 4 | 80 | 20 | 15.78 |
| 200 | 13 | 7 | 65 | 35 | 31.57 | |
|
| 100 | 13 | 7 | 65 | 35 | 31.57 |
| 200 | 10 | 10 | 50 | 50 | 47.36 | |
|
| 100 | 9 | 11 | 45 | 55 | 52.63 |
| 200 | 7 | 13 | 35 | 65 | 63.15 | |
|
| 100 | 11 | 9 | 55 | 45 | 42.10 |
| 200 | 8 | 12 | 40 | 60 | 57.89 | |
|
| 100 | 7 | 13 | 35 | 65 | 63.15 |
| 200 | 5 | 15 | 25 | 75 | 73.68 | |
|
| 100 | 11 | 9 | 55 | 45 | 42.10 |
| 200 | 6 | 14 | 30 | 70 | 68.42 | |
| Control | — | 19 | 1 | 95 | 5 | — |
Pupicidal screening data of the ligand and its silicon complexes (100 and 200 are concentrations in ppm).
| Ligand/complex | Dose level | Average no. of | Average no. of | % emerged | % pupal | % corrected |
| adults emerged | pupal mortality | adult | mortality | mortality | ||
|
| ||||||
|
| 100 | 15 | 5 | 75 | 25 | 21.05 |
| 200 | 14 | 6 | 70 | 30 | 26.31 | |
|
| 100 | 14 | 6 | 70 | 30 | 26.31 |
| 200 | 11 | 9 | 55 | 45 | 42.10 | |
|
| 100 | 10 | 10 | 50 | 50 | 47.36 |
| 200 | 6 | 14 | 30 | 70 | 68.42 | |
|
| 100 | 12 | 8 | 60 | 40 | 38.84 |
| 200 | 8 | 12 | 40 | 60 | 57.89 | |
|
| 100 | 9 | 11 | 45 | 55 | 52.63 |
| 200 | 5 | 15 | 25 | 75 | 73.68 | |
|
| 100 | 11 | 9 | 55 | 45 | 42.10 |
| 200 | 7 | 13 | 35 | 65 | 63.15 | |
| Control | — | 19 | 1 | 95 | 5 | — |
Bactericidal screening data of the ligand and its silicon complexes diameter inhibition zone (mm) after 24 hours (500 and 1000 are concentrations in ppm).
| Ligand/complex |
|
|
|
| ||||
|
| ||||||||
| 500 | 1000 | 500 | 1000 | 500 | 1000 | 500 | 1000 | |
|
| ||||||||
| (2-Ac-F-StH) | 6 | 6 | 6 | 11 | 10 | 12 | 9 | 13 |
|
| 8 | 12 | 9 | 15 | 12 | 14 | 12 | 14 |
|
| 10 | 16 | 11 | 17 | 15 | 17 | 16 | 18 |
|
| 10 | 14 | 10 | 16 | 14 | 16 | 15 | 16 |
|
| 13 | 18 | 14 | 19 | 17 | 19 | 18 | 19 |
|
| 11 | 16 | 12 | 17 | 15 | 17 | 16 | 17 |
| Streptomycin | 1 | 2 | 3 | 5 | 2 | 5 | 15 | 17 |
Nematicidal screening data of the ligand and its silicon complexes (25, 50, and 100 are concentrations in ppm).
| Ligand/complex | (% of hatching | ||
|
| |||
| 25 | 50 | 100 | |
|
| |||
|
| 22.5 | 19.0 | 15.0 |
|
| 20.2 | 16.5 | No hatching |
|
| 18.5 | 14.9 | No hatching |
|
| 19.6 | 16.4 | No hatching |
|
| 15.9 | 11.9 | No hatching |
|
| 18.6 | 14.0 | No hatching |